Does BadgerCare Cover Wegovy & Zepbound in 2026? (PA Rules)

Direct answer – BadgerCare and GLP-1s in 2026

Yes – as of June 2026, BadgerCare Plus and Wisconsin Medicaid cover Wegovy, Zepbound, and Saxenda for weight loss through ForwardHealth prior authorization – but approval is capped at 12 continuous months, renewal requires losing at least 5% of your starting weight, and ForwardHealth allows only two weight-loss attempts per drug.

That makes Wisconsin one of roughly 13 state Medicaid programs still covering GLP-1s for obesity as of January 2026, per KFF tracking – and one of the longest-standing. ForwardHealth, the system that administers Wisconsin Medicaid and BadgerCare Plus pharmacy benefits, has paid for prior-authorized anti-obesity drugs since at least 2009, long before TennCare and most other states added GLP-1 benefits in 2024 and 2025. The trade-off is that Wisconsin pairs that long history with some of the strictest duration and renewal rules in the country. For the national picture, see our Medicaid GLP-1 coverage by state guide. Everything below is Wisconsin-specific.

Important – verify your specific plan

BadgerCare Plus members are enrolled in different HMOs across Wisconsin, but for most members, pharmacy prior-authorization decisions for these drugs come from ForwardHealth itself, not your BadgerCare Plus HMO. That means the criteria in this guide apply statewide. If you want to confirm your own coverage before starting the process, call ForwardHealth member services at 800-362-3002.

One timing caution: as of June 2026, ForwardHealth has an active shortage advisory telling prescribers not to start an anti-obesity drug prior authorization unless the drug is confirmed to be available at a specific pharmacy. Ask your pharmacy about stock before your prescriber submits paperwork. This guide describes plan policy as of June 2026 and is educational only – it is not medical or insurance advice, and meeting the criteria on paper is not a guarantee of approval.

BadgerCare GLP-1 coverage at a glance

Drug	BadgerCare status (2026)	Prior authorization?	Key limit
Wegovy (semaglutide)	Covered for weight loss, ages 12+	Yes – form F-00163	12-month cap, 5% renewal rule, two lifetime attempts (heart-risk and MASH pathways exempt)
Zepbound (tirzepatide)	Covered for weight loss, adults 18+ only	Yes – form F-00163	Same 12-month cap and renewal rules; sleep-apnea pathway has no lifetime limit
Saxenda (liraglutide)	Covered for weight loss, ages 12+	Yes – form F-00163	Same duration rules; separate teen criteria
Ozempic (semaglutide)	Type 2 diabetes only – preferred since July 2025	Yes – diagnosis-restricted	Not approvable for weight loss alone
Mounjaro (tirzepatide)	Type 2 diabetes only – non-preferred	Yes – diagnosis-restricted	Requires trial of two preferred diabetes agents first
Older oral agents (phentermine, orlistat, phentermine/topiramate, others)	Covered for weight loss	Yes	Same ForwardHealth anti-obesity rules and attempt limits

The full covered anti-obesity roster also includes benzphetamine, diethylpropion, orlistat (generic and brand Xenical), phendimetrazine, and Evekeo, per ForwardHealth’s anti-obesity drug policy. According to the Pharmacy Society of Wisconsin’s anti-obesity medication toolkit, SeniorCare Levels 1 and 2A follow the same coverage as well.

BadgerCare requirements for Wegovy and Zepbound

ForwardHealth’s criteria are spelled out on prior authorization form F-00163 (11/2025 revision). To be approved as of June 2026, you need:

BMI of 30 or higher, OR BMI of 27-29.9 with two or more weight-related risk factors – dyslipidemia, hypertension, obstructive sleep apnea, type 2 diabetes, or cardiovascular disease.
Age 18 or older for most drugs. Wegovy, Saxenda, Xenical/orlistat, phentermine-topiramate, and Evekeo are allowed from age 12 with extra pediatric criteria. Zepbound is 18+ only.
A documented weight-loss treatment plan within the past 6 months – nutritional counseling, an exercise program, or a calorie-restricted diet – plus a stated commitment to continue it during treatment.
No exclusions. Pregnancy or nursing, a history of an eating disorder, or a history of substance misuse each rule out approval.

Wisconsin requires two weight-related conditions at BMI 27-29.9 – stricter than the FDA label, which requires one. That single line is what trips up the most otherwise-eligible applicants in the 27-29.9 range. If you are not sure where you fall, our guide on how to qualify for GLP-1 weight loss treatment walks through BMI math and the common qualifying conditions.

Wegovy on BadgerCare (2026)

Wegovy is covered by BadgerCare Plus and Wisconsin Medicaid for weight loss with prior authorization, as of June 2026. Once you are approved, the calendar matters more than almost anything else in Wisconsin’s policy. Per ForwardHealth Online Handbook Topic #7837:

Initial approval runs up to 183 days (6 months).
Renewal requires losing at least 5% of your baseline weight during that initial period. ForwardHealth will also not renew if your BMI has dropped below 24.
Coverage is capped at 12 continuous months, followed by a mandatory 6-month wait before a new request.
Two weight-loss attempts per drug, lifetime, per ForwardHealth policy as of June 2026.
Only one anti-obesity drug at a time – no combining Wegovy with phentermine or any other covered agent.

On quantity, ForwardHealth publishes duration limits rather than per-fill quantity limits, and approvals generally run up to FDA-labeled maintenance dosing, as of June 2026.

These limits are enforced literally. In one published case, the Wisconsin Division of Hearings and Appeals dismissed a member’s appeal (decision MPA 215583, December 9, 2024) after the member had completed 12 continuous months of Wegovy and had not yet served the 6-month wait – the policy left nothing for a hearing officer to overturn. Treat the 12-month cap as a hard wall, not a negotiating position.

Two Wegovy pathways sit outside these weight-loss limits entirely. Per Topic #7837 and the PSWI toolkit as of June 2026, Wegovy prescribed for cardiovascular risk reduction or for MASH (metabolic dysfunction-associated steatohepatitis) carries no lifetime attempt limit. If you have established cardiovascular disease, ask your prescriber which indication fits your chart.

Zepbound on BadgerCare (2026)

Zepbound is covered by BadgerCare Plus for weight loss with prior authorization – but only for adults 18 and older, as of June 2026. Unlike Wegovy and Saxenda, there is no adolescent pathway for Zepbound on ForwardHealth’s criteria; the F-00163 form simply does not allow it under 18.

For adults, every Wegovy rule above applies identically: up to 183 days initially, renewal only with at least 5% weight loss from baseline, a 12-continuous-month cap, a 6-month wait afterward, and two lifetime weight-loss attempts per drug, per ForwardHealth policy as of June 2026. Note that attempts are counted per drug – a failed Wegovy attempt does not erase your Zepbound attempts, and vice versa, but each drug’s count is finite.

One Zepbound pathway escapes the lifetime limit: Zepbound for moderate-to-severe obstructive sleep apnea is a separate indication with no lifetime attempt limit under Topic #7837, as of June 2026. If you have a sleep-study-documented OSA diagnosis, that route may matter more than the weight-loss criteria.

Ozempic on BadgerCare (2026)

BadgerCare does not cover Ozempic for weight loss. Ozempic is covered only for type 2 diabetes, where it has been a preferred drug on the ForwardHealth preferred drug list since July 1, 2025 – a status confirmed on the January 1, 2026 PDL quick reference. All GLP-1 diabetes agents are diagnosis-restricted: approval requires a type 2 diabetes diagnosis supported by an HbA1c result from within the past 6 months.

Mounjaro, by contrast, is non-preferred for diabetes on the same list, and non-preferred GLP-1s require a documented trial of two preferred agents first. If your goal is weight loss without a diabetes diagnosis, the covered lane on BadgerCare runs through Wegovy, Zepbound, or Saxenda – not Ozempic or Mounjaro.

Saxenda on BadgerCare – the teen-eligible option

Saxenda is covered by BadgerCare Plus for weight loss with prior authorization from age 12, as of June 2026. For members aged 12-17, ForwardHealth requires body weight above 132 pounds plus a BMI equivalent to 30 or higher for an adult. Wegovy is also available from age 12, with a different pediatric standard – a BMI at or above the 95th percentile for age and sex.

For adults, Saxenda follows the same duration framework as the other GLP-1s: 183-day initial approval, the 5% renewal rule, the 12-month cap with 6-month wait, and two lifetime attempts per drug, per ForwardHealth policy as of June 2026. Practically, Saxenda is a daily injection versus Wegovy’s weekly dosing, so most adult requests favor Wegovy – Saxenda’s distinct value on BadgerCare is the adolescent pathway.

The rules that changed in 2024 and 2025

Wisconsin’s coverage did not appear with the GLP-1 era – it predates it by more than a decade. The key milestones:

2009: ForwardHealth Update 2009-53 establishes prior-authorized anti-obesity drug coverage. Wisconsin has covered this category since at least then.
Mid-2023: Wisconsin is one of just nine states with Wegovy on its Medicaid preferred list, per AP reporting.
July 1, 2024: Update 2024-16 standardizes PA criteria across all anti-obesity drugs and formalizes the 12-continuous-month cap.
July 1, 2025: Update 2025-16 adds generic orlistat to the covered roster; the same date, Ozempic becomes preferred for type 2 diabetes.
November 2025: The PA form F-00163 is revised (the 11/2025 version is current as of June 2026).

Three things are worth watching. First, the national tide is going out: KFF counts roughly 13 covering state Medicaid programs as of January 2026, down from 16, after California, New Hampshire, and South Carolina ended coverage on January 1, 2026 and North Carolina in September 2025. Second, Stateline reported in November 2025 that Wisconsin is “considering new restrictions” – that is unconfirmed reporting, and no policy change has been announced as of June 2026. Third, Wisconsin had not announced participation in the federal BALANCE Model for discounted GLP-1 pricing as of June 2026; state applications remain open through July 31, 2026. If you are starting a PA now, current rules apply – but do not assume they are permanent.

What if BadgerCare denies your GLP-1 prescription?

Most denials trace back to a short list of causes:

Missing lifestyle documentation – no record of nutritional counseling, exercise, or a calorie-restricted diet within the past 6 months.
Missing or stale BMI and comorbidity documentation, especially the two-condition requirement at BMI 27-29.9.
The 12-month cap was reached, or the 6-month wait has not been served.
Lifetime attempts for that drug are used up, per ForwardHealth policy as of June 2026.
The shortage advisory – PAs started without confirming the drug is available at a specific pharmacy.

Resubmit before you appeal. If the denial is a documentation gap, the fastest fix is for your prescriber to correct and resubmit form F-00163 with the missing records – no hearing required. If you believe ForwardHealth applied its own policy incorrectly, you can request a fair hearing through the Wisconsin Division of Hearings and Appeals; follow the deadline printed on your denial notice. Be realistic about what a hearing can do: as the MPA 215583 case showed, an appeal cannot override a clearly written limit like the 6-month wait. Hearings help when the facts were wrong, not when the policy is unwelcome.

GLP-1 alternatives for BadgerCare members in 2026

If you do not meet ForwardHealth’s criteria, have hit the 12-month cap, are mid-wait, or have used your attempts, the remaining route is cash-pay telehealth. To be clear: these are cash-pay programs you fund out of pocket – they are not Medicaid benefits, and they sit entirely outside ForwardHealth’s rules. You can compare the leading weight-loss telehealth providers here; three worth knowing:

Ro Body Program

Ro’s Body Program pairs GLP-1 prescriptions (where clinically appropriate) with provider oversight, insurance-paperwork support, and ongoing coaching. For BadgerCare members, Ro is most relevant if you fall short of ForwardHealth’s PA criteria – say, one qualifying condition at BMI 27-29.9 instead of two – or want a cash-pay route that is not subject to the 12-month cap. See Ro Body Program pricing. Read our full Ro review for every plan and price.

Remedy Meds

Remedy Meds is a telehealth weight-loss program built around straightforward cash pricing, with no insurance or prior authorization involved. That makes it a common fallback for people whose Medicaid PA was denied or not renewed – including BadgerCare members sitting out the mandatory 6-month wait. See Remedy Meds pricing. Our full Remedy Meds review covers the program in detail.

Trim Rx

Trim Rx is a cash-pay compounded telehealth program with flat published pricing – oral semaglutide from $179/month and tirzepatide at $349/month flat at every dose, as of June 2026 – with no insurance or prior authorization involved. It is a young company (founded 2024), so see our Trim Rx review for the complaint patterns and billing terms before you commit.

How to apply for prior authorization

Gather your documentation with your prescriber – current BMI, any qualifying conditions (you need two at BMI 27-29.9), and proof of a weight-loss treatment plan within the past 6 months.
Confirm pharmacy availability first. Under the active shortage advisory, prescribers should not start an anti-obesity PA unless the drug is confirmed in stock at a specific pharmacy.
Have your prescriber complete form F-00163 (use the 11/2025 revision).
Submit it via the ForwardHealth Portal, fax, mail, or the Drug Authorization and Policy Override (DAPO) Center.
Wait for the decision. ForwardHealth decides within 20 working days of receiving complete information – incomplete submissions restart the clock.
Questions along the way? Call ForwardHealth member services at 800-362-3002.

Frequently asked questions

Does BadgerCare cover Wegovy for weight loss?

Yes. As of June 2026, BadgerCare Plus and Wisconsin Medicaid cover Wegovy for weight loss with ForwardHealth prior authorization. Initial approval runs up to 183 days, renewal requires losing at least 5% of baseline weight, and coverage is capped at 12 continuous months.

Does BadgerCare cover Zepbound?

Yes, for adults 18 and older. As of June 2026, BadgerCare Plus covers Zepbound for weight loss with prior authorization under the same 12-month cap and 5% renewal rule as Wegovy. Zepbound for moderate-to-severe obstructive sleep apnea follows a separate pathway with no lifetime limit.

Does BadgerCare cover Ozempic for weight loss?

No. ForwardHealth covers Ozempic only for type 2 diabetes, where it has been a preferred drug since July 1, 2025. For weight loss, BadgerCare members need Wegovy, Zepbound, or Saxenda – all of which require prior authorization.

What BMI do you need for BadgerCare to approve a GLP-1?

A BMI of 30 or higher, or 27-29.9 with at least two weight-related conditions such as hypertension, sleep apnea, or type 2 diabetes. If you are exploring weight loss surgery instead, BadgerCare covers bariatric procedures under separate criteria – ask your provider.

How long will BadgerCare cover Wegovy or Zepbound?

Up to 12 continuous months per attempt: an initial approval of up to 183 days, plus a renewal if you have lost at least 5% of baseline weight. After 12 months, ForwardHealth requires a 6-month wait, and allows two weight-loss attempts per drug, per policy as of June 2026.

What happens at renewal if I haven’t lost 5% of my weight?

ForwardHealth will not renew the prior authorization. Under BadgerCare policy as of June 2026, falling short of 5% weight loss from baseline ends that course of treatment, and it counts toward the drug’s lifetime attempts. Your prescriber can consider a different covered anti-obesity drug, which has its own attempt count.

Can teenagers get Wegovy through BadgerCare?

Yes. ForwardHealth allows Wegovy from age 12 with prior authorization; members aged 12-17 need a BMI at or above the 95th percentile for age and sex. Saxenda is also available from age 12 (over 132 pounds plus an adult-equivalent BMI of 30). Zepbound is adults-only.

Does BadgerCare Cover GLP-1 Weight Loss Drugs in 2026?